Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from DiagnosTear Technologies, Inc. ( (TSE:DTR) ) is now available.
DiagnosTear Technologies reported highly encouraging interim clinical results from its ongoing multi-center study in Israel evaluating its TeaRx Red Eye diagnostic platform, which is designed to rapidly distinguish between adenoviral conjunctivitis, herpetic keratitis and allergic conjunctivitis at the point of care. In 130 enrolled subjects, TeaRx Red Eye showed strong agreement with established laboratory methods, including positive and negative agreement rates of 92% and 100% for adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, suggesting reliable identification of viral red-eye causes and improved treatment decisions. The Israeli trial, alongside complementary programs in India and France focused on HSV and allergic conjunctivitis, is expected to conclude by the second quarter of 2026 and is intended to underpin regulatory submissions and global commercialization in major markets such as the US and EU, potentially strengthening DiagnosTear’s competitive position in the emerging market for rapid ocular diagnostics and reducing unnecessary antibiotic and antiviral use.
More about DiagnosTear Technologies, Inc.
DiagnosTear Technologies Inc. is a Vancouver-based developer of rapid, point-of-care diagnostic tests for ocular diseases, specializing in multi-parametric tear-fluid analysis. The company positions itself as a global leader in ophthalmic diagnostics, aiming to provide fast, clinically actionable insights to support precise, data-driven decision-making for primary care and eye-care providers.
Average Trading Volume: 39,258
Technical Sentiment Signal: Strong Buy
Learn more about DTR stock on TipRanks’ Stock Analysis page.